Proton RT for the Treatment of Pediatric Rhabdomyosarcoma



Status:Recruiting
Conditions:Cancer
Therapuetic Areas:Oncology
Healthy:No
Age Range:Any - 21
Updated:3/31/2019
Start Date:October 2004
End Date:June 2020
Contact:Torunn Yock, MD
Phone:617-724-1836

Use our guide to learn which trials are right for you!

A Phase II Trial of Proton RT for the Treatment of Pediatric Rhabdomyosarcoma

The main purpose of this study is to see if using proton beam radiation therapy instead of
photon beam radiation therapy can reduce side effects from radiation treatment for
rhabdomyosarcoma. Photon beam radiation is the standard type of radiation for treating most
rhabdomyosarcoma and many other types of cancer. Photon beam radiation enters the body and
passes through healthy tissue, encounters the tumor, then leaves the body through healthy
tissue. A beam of proton radiation enters the body and passes through healthy tissue,
encounters tumor, but then stops. This means that less healthy tissue is affected by proton
beam radiation than by photon beam radiation.

- A special device is made for each participant to help them hold still during the
treatment. This may be in the form of a mask or a custom made foam cradle depending on
the area to be treated.

- Radiation treatments will be given once per day, 5 days a week for a total of 4 to 6
weeks, depending upon how much total dose the tumor requires.

- Participants will be seen once per week by their radiation doctor to monitor health and
record any side effects from treatment.

- After the radiation treatments are completed, participants will be required to undergo
further tests and evaluations for several years following treatment.

Inclusion Criteria:

- Patients with biopsy proven newly diagnosed rhabdomyosarcoma.

- Patients less than or equal to 21 years of age.

- Patients must be treated with a standardly accepted chemotherapy regimen.

- May not have metastatic disease unless aged 2-10 with embryonal histology.

- Must be willing to receive follow-up care for a minimum of five years after treatment
at MGH and annual visits unless it is too difficult to return to MGH for follow-up
care. In that event, they must be willing to have their outside medical information
released to us to track the results.

- Timing of radiation must be according to the IRB protocol upon which the patient is
treated within either 35 days of last chemotherapy or surgery.

Exclusion Criteria:

- Life expectancy of less than 2 years.

- Co-morbidities that would make the use of radiation too toxic to deliver safely, such
as serious local injury or collagen vascular disease.

- Patients who are pregnant

- Previous treatment with radiation therapy.
We found this trial at
3
sites
450 Brookline Ave
Boston, Massachusetts 2215
617-632-3000
Principal Investigator: Karen Marcus, MD
Dana-Farber Cancer Institute Since it’s founding in 1947, Dana-Farber has been committed to providing adults...
?
mi
from
Boston, MA
Click here to add this to my saved trials
185 Cambridge Street
Boston, Massachusetts 02114
617-724-5200
Principal Investigator: Torunn Yock, MD
?
mi
from
Boston, MA
Click here to add this to my saved trials
1515 Holcombe Blvd
Houston, Texas 77030
 713-792-2121
Principal Investigator: Anita Mahajan, MD
University of Texas M.D. Anderson Cancer Center The mission of The University of Texas MD...
?
mi
from
Houston, TX
Click here to add this to my saved trials